Page 60 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $3.29
52wk Low $1.55 Cocrystal Pharma, Inc. COCP $1.64
19805 North Creek Parkway
Bothell, WA 98011

(USD - in millions) www.cocrystalpharma.com
Market Cap 16.7
Enterprise (12.9)
Basic Shares Out. 10.17 COMPANY OVERVIEW
Float 7.12
Institutional Holdings 6.89% Detailed Analysis:Channelchek.com
Short Interest 0.01
Avg. 90-Day Volume 0.03 Cocrystal Pharma, Inc. is a clinical-stage biotechnology company
discovering and developing novel antiviral therapeutics that target the
replication process of influenza viruses, coronaviruses (including SARS-
CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique
EPS Data structure-based technologies and Nobel Prize-winning expertise to
create first- and best-in-class antiviral drugs.
2021 2022 2023
CQ1 (0.48) (0.48) (0.64)
CQ2 (0.48) (0.46) (0.50)

CQ3 (0.48) (0.70) (0.41)
CQ4 (0.48) (0.54) (0.61)
CY (1.92) (2.23) (2.14) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 3.02
ROE (ttm) -48.31
Debt-to-Total Cap. (mrq) 0.38
Fiscal Year End 31-Dec

19805 North CBothell WA 98011

Key Executives
CEO: N/A
CFO: Martin, James
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures